Orexo starts clinical study of nasal rescue medication – challenging established market
Allergy firm ALK could face new competition on the market for the emergency treatment of allergic reactions, as the Swedish biotech firm will test its nasal candidate against today’s first-line, intramuscular injection treatments.
by christian bundgaard, translated by daniel pedersen
Swedish biotech firm Orexo is ready to enter the clinical stage with a nasal candidate, OX640, for the emergency treatment of allergic reactions, which includes anaphylaxis, a company press release has announced.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
ALK still has two horses in adrenaline race
For subscribers
